Insight Wealth Strategies LLC Has $6.81 Million Stock Holdings in Merck & Co., Inc. $MRK

Insight Wealth Strategies LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 8.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,323 shares of the company’s stock after acquiring an additional 4,035 shares during the quarter. Insight Wealth Strategies LLC’s holdings in Merck & Co., Inc. were worth $6,810,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in Merck & Co., Inc. in the fourth quarter worth $3,997,933,000. Wellington Management Group LLP boosted its position in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $1,012,530,000. Jennison Associates LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $585,192,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after buying an additional 5,152,069 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA and European Medicines Agency accepted supplemental applications to expand ENFLONSIA, Merck’s RSV preventive therapy, to additional high-risk young children. The potential broader indication could expand Merck’s infectious-disease portfolio and help diversify revenue beyond oncology. Merck Wins FDA and EMA Review for Broader RSV Use in Children
• Positive Sentiment: Argus raised its price target on MRK from $130 to $145 and reiterated a “buy” rating, adding to a generally favorable analyst view. Recent targets from other firms have also reached the $146–$150 range, reflecting confidence in Keytruda, animal health and the development pipeline.
• Positive Sentiment: Merck’s latest quarterly results exceeded expectations, with revenue of $16.61 billion versus a $16.37 billion consensus estimate and revenue growth of 5.1% year over year. Oncology and animal health were key contributors, while the company maintained 2026 adjusted EPS guidance of $2.66–$2.76. Merck Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Merck declared a quarterly dividend of $0.85, equivalent to $3.40 annually and a yield of roughly 2.6%. The dividend supports the stock’s income appeal, although the reported payout ratio is elevated because current earnings are depressed by unusual factors.
• Neutral Sentiment: Reports discussing a proposal to separate the measles, mumps and rubella vaccine into three shots could create uncertainty around Merck’s vaccine business, including MMR II. Experts say the plan lacks scientific support and is unlikely to proceed. Trump Wants to Split the MMR Vaccine
• Negative Sentiment: Analysts continue to flag falling estimates and the risk from upcoming Keytruda patent expirations, which could pressure Merck’s near-term growth and valuation despite strong current sales and pipeline progress. MRK Stock Up 5.6% in a Month as Estimates Fall
• Negative Sentiment: Executive Vice President Richard Deluca sold 6,050 shares worth approximately $788,799. The sale reduced his holdings by 3.75%, though he continues to own a substantial position and the transaction alone is not necessarily a signal of deteriorating fundamentals. Merck EVP Sells Stock

Merck & Co., Inc. Trading Down 0.4%

Shares of NYSE:MRK opened at $130.35 on Wednesday. The firm has a market cap of $321.59 billion, a price-to-earnings ratio of 104.28, a PEG ratio of 5.66 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.05. The company’s fifty day simple moving average is $124.58 and its 200 day simple moving average is $119.47. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Analyst Ratings Changes

MRK has been the topic of several research analyst reports. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target for the company. BMO Capital Markets raised their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Scotiabank lifted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Fourteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $135.11.

Insider Transactions at Merck & Co., Inc.

In related news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares in the company, valued at approximately $6,106,303. This represents a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 92,603 shares of company stock valued at $11,966,744 over the last three months. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.